Home > GP Information > GP Symposium 2019
GP Symposium Programme - Saturday 19th October 2019
Waipuna Conference Centre, Mt Wellington
Conversations about Cardiology Cases:
"Cardiology in the home or hospital?"
Workshops: Repeated Sessions: 0735 – 0820am , 0825 – 0910am
Most syncopal events have a benign cause, but when should we worry. This session will help highlight the red flags and identify who should be referred for urgent assessment
Of itself being diagnosed with a cardiac condition can cause enough worry for an individual. The impact on their ability to work is often not appreciated. Restrictions may be placed on driving / flying or diving. We often have a legal obligation to advise on this. The session will review current recommendations that we must be aware of and our responsibility
Exercise is a key part of any primary preventative program, and often a therapeutic part of a treatment program once cardiac disease is identified. This session will recommendations for exercise in patients with cardiac disease – who we should restrict and who can be unrestricted + how to assess who is safe to push themselves
BREAK (0910-0920)
Main sessions :
Introduction and admin: 9:20 - 0930
Heart failure : 9:30 to 10:45: Chair: Ted Clarke
Heart failure remains a clinical diagnosis with investigations supporting it and helping identify aetiology / guide on Rx + assess response to treatment. Non pharmacological therapy is an important part of management of any disease. This session will review how we diagnosis heart failure in 2019 and the importance of lifestyle measures in management
We are all familiar with diuretics, ACEi inhibitors / ARBs , β-blockers and MRAs (mineralocorticoid antagonists) and their importance in heart failure management, but what is “optimum medical treatment” in 2019. What new agents are available and where do they fit?
MORNING TEA (1045 – 1115)
Arrhythmias: 11:15 to 1245: Chair: Jim Stewart
Atrial fibrillation
When a patient presents with AF how to we decide who should be rate controlled and who should we treat with a rhythm control approach. If pursuing a rhythm control approach who should be referred acutely for cardioversion and who for a delayed one. This session will address these issues
Choosing the right anticoagulant strategy for any individual with AF is the most important aspect of their management. But no pill / aspirin / warfarin or NOAC? And which NOAC? This session will review the role each has to play in management and guide on choice / duration and monitoring of each agent
More and more patients have implanted cardiac devices (pacemakers / ICDs) that generate reports with diagnostic information – this may relate to arrhythmias, or even fluid status. On top of this the usage of smart technology with heart rate monitoring or even single lead ECG technology is increasing rapidly, providing patients with information. This session will cover how to interpret a pacemaker report and what are the key factors to miss, along with some discussion of managing the flood f smart technology information
LUNCH TIME SESSION (1245 to 1345)
INTRA education session (1300 – 1330)
Prevention: (1345 – 1545) Chair: Peter Ruygrok
The place of aspirin in preventative cardiology is constantly changing. There is no question of its role in secondary prevention, but what are the current recommendations for 2019 – this session will review who should be on aspirin for primary prevention
(1515 – 1545)
Pro: Colin Edwards Con: Chris Ellis
Closing remarks: 1545 – 1600 (Malcolm Legget)